An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Monopar Therapeutics Inc. announced that its abstract on the preclinical data for its radiopharmaceutical program MNPR-101-Zr has been selected for a presentation at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting in Toronto, Canada. The event, scheduled from June 8 to June 11, 2024, is a significant platform for showcasing innovative treatments for cancer patients.
Monopar Therapeutics Inc. ha annunciato che il suo abstract sui dati preclinici del programma radioterapeutico MNPR-101-Zr è stato selezionato per una presentazione all'Incontro Annuale 2024 della Society of Nuclear Medicine and Molecular Imaging a Toronto, Canada. L'evento, in programma dall'8 all'11 giugno 2024, rappresenta una piattaforma importante per presentare trattamenti innovativi per i pazienti affetti da cancro.
Monopar Therapeutics Inc. anunció que su resumen sobre los datos preclínicos de su programa radiofarmacéutico MNPR-101-Zr ha sido seleccionado para una presentación en la Reunión Anual 2024 de la Sociedad de Medicina Nuclear e Imagen Molecular en Toronto, Canadá. El evento, programado del 8 al 11 de junio de 2024, es una plataforma significativa para mostrar tratamientos innovadores para pacientes con cáncer.
Monopar Therapeutics Inc.는 자사의 방사성 의약품 프로그램 MNPR-101-Zr에 대한 전임상 데이터 요약이 캐나다 토론토에서 열리는 2024년 핵의학 및 분자 영상학회 연례 회의에서 발표될 것으로 선정되었다고 발표했습니다. 2024년 6월 8일부터 6월 11일까지 예정된 이 행사는 암 환자를 위한 혁신적인 치료법을 소개하는 중요한 플랫폼입니다.
Monopar Therapeutics Inc. a annoncé que son résumé sur les données précliniques de son programme radiopharmaceutique MNPR-101-Zr a été sélectionné pour une présentation lors de la Réunion Annuelle 2024 de la Société de Médecine Nucléaire et d'Imagerie Moléculaire à Toronto, Canada. L'événement, prévu du 8 au 11 juin 2024, est une plateforme significative pour la présentation de traitements innovants pour les patients atteints de cancer.
Monopar Therapeutics Inc. gab bekannt, dass sein Abstract über präklinische Daten des radiopharmazeutischen Programms MNPR-101-Zr für eine Präsentation auf der Jahrestagung 2024 der Society of Nuclear Medicine and Molecular Imaging in Toronto, Kanada, ausgewählt wurde. Die Veranstaltung, die vom 8. bis zum 11. Juni 2024 geplant ist, stellt eine bedeutende Plattform zur Präsentation innovativer Behandlungen für Krebspatienten dar.
Positive
None.
Negative
None.
WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) submitted to the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting has been selected for a presentation. SNMMI 2024, held in Toronto, Canada, is recognized as the premier educational, scientific, and research event in the radiopharma space.
Meeting Details:
Event: Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting
Date: June 8 – June 11, 2024
Location: Metro Toronto Convention Centre, Toronto, ON, Canada
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of Phase 1-stage MNPR-101 for radiopharmaceutical use in various advanced cancers; Phase 1b-stage camsirubicin for the treatment of advanced soft tissue sarcoma; and an early-stage camsirubicin analog, MNPR-202. For more information, visit: www.monopartx.com and ir.monopartx.com/presentations.
CONTACT:
Monopar Therapeutics Inc. Investor Relations Kim R. Tsuchimoto Chief Financial Officer kimtsu@monopartx.com
What did Monopar Therapeutics announce regarding its radiopharmaceutical program MNPR-101-Zr?
Monopar Therapeutics announced that its abstract on the preclinical data for its radiopharmaceutical program MNPR-101-Zr has been selected for a presentation at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.
When is the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting scheduled to take place?
The SNMMI 2024 Annual Meeting is scheduled to take place from June 8 to June 11, 2024.
Where will the SNMMI 2024 Annual Meeting be held?
The SNMMI 2024 Annual Meeting will be held at the Metro Toronto Convention Centre in Toronto, ON, Canada.
monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.
